Blue Jet Healthcare Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ivudpf2jw6df5u62rvjqglzx.pdf

Key Takeaways


The Cardiovascular Intermediate: The Quarter’s Engine

VK Singh: "Today, there are 9,000 cardiologists in the US who are prescribing this and this has become the primary line of treatment. Earlier it was the secondary line of treatment. Because of the label update and label expansion, both in the US and Europe, I think the addressable market of this has grown 7x of what it used to be."

Contrast Media: Stabilizing, Not Yet Growing


Capacity Expansion: The Multi-Year Buildout

VK Singh: "We have two types of growth in our business. One is the secular growth that we get because the market is growing. The second is each time we forward integrate that we give a more advanced intermediate. Sometimes the value is, 2x-3x from the same capacity."

Margins, Costs & Working Capital


Pipeline, R&D & New Opportunities


Housekeeping & Risks

Shiven Arora: "Even if they evaluate others, I think that is what Ganesh mentioned."

Guidance & Commitments

CommitmentSpecificsTimeline
Iodinated contrast intermediate commercializationCommercial launch expected; full potential in FY27H1 FY26
Mahad Unit-3 backward integration plantContinuous-process plant for feedstock and derivatives, on streamH2 FY26
Mahad MPP (GMP, ~30 reactors)Versatile plant with clean rooms, milling, single-fluid systems, on streamH2 FY27
Fund-raise details disclosedMore visibility on the ₹1,500 crore raiseImmediate quarter (Q1 FY26)
Baseline CAPEX (ex-Dahej, ex-new sites)~₹300 crore plus, up from ~₹200 crore earlierFY26
Capacity bottleneckNo bottleneck seenNext two years

Key Metrics

MetricQ4 FY25
Revenue (FY25)₹1,030 cr, +45% YoY
EBITDA (FY25)₹377.7 cr, margin of 37%, up 65% YoY
PAT (FY25)₹305.2 cr, up 87% YoY
EPS (FY25)₹17.59 per share, compared to ₹9.44 in FY24
Q4 revenue growth+6.9% QoQ
Q4 EBITDA growth+12.9% QoQ
PI/API segment revenue growth (FY25)+388% YoY
Contrast media segment revenue growth (FY25)-15.8% YoY
Artificial sweeteners revenue (FY25)₹133 cr, +4.1% YoY
Artificial sweeteners gross margin (FY25)15.2%, flat YoY
Artificial sweeteners operational EBITDA margin (FY25)36.7%, up 4.4% YoY
Cash and treasury investments₹284.8 cr as on March 31, 2025
Cash conversion cycle139 days, compared to 135 days in Q4 FY24
Working capital increase~₹250 cr, one-time increase to support higher activity levels
Overall capacity utilization~75% across all segments
PI/API capacity utilization60–65% for FY25
CWIP (FY25)₹89 cr
Fresh CAPEX planned (FY26)~₹300 cr, excluding new sites or Dahej
Unit-3 Mahad CAPEX~₹300 cr, increased from earlier plan of ~₹250 cr
Process excellence initiative CAPEX commitment~₹60 cr
R&D center CAPEX commitment₹40 cr
New capacity added (Unit-2 Ambernath)157 KL across two phases
Dividend declared₹1.20 per share, subject to shareholder approval
Pharma intermediate molecules tracked28 molecules, up from 22 in the previous quarter
Late-stage opportunities (phase 3 or commercial)~30% of 20 new opportunities being tracked
Cardiovascular intermediate Q4 revenue~₹200 cr
Cardiovascular molecule prescribers (US)9,000 cardiologists
Cardiovascular molecule addressable market expansion7x due to label expansion
De-bottlenecking potential (PI/API)~20% additional capacity, achievable in 8–9 weeks
Income tax notice₹200 cr, Company comfortable with its stand